Sökresultat - Zhiming Li
-
1
An Aliasing Measure of Factor Effects in Three-Level Regular Designs
Publicerad 2025-06-01Hämta fulltextFor three-level regular designs, the confounding from the perspectives of both factor and component effects leads to different results. The aliasing properties of factor effects are more significant than the latter in the experimental model. In this paper, a new three-level aliasing pattern is propo...
Artikel -
2
Statistical Analysis of a Generalized Linear Model for Bilateral Correlated Data Under Donner’s Model
Publicerad 2025-06-01Hämta fulltextPaired data often arise in medical studies, with a correlation between responses of paired organs or parts. Under an intra-correlated model, this paper proposes a generalized linear model to investigate probable confounding factors of the individual response rates in paired data. The main link funct...
Artikel -
3
Experimental Evaluation of the Average Energy for Impact Ionization by Holes in Al0.4Ga 0.6N Alloy
Publicerad 2017-01-01Hämta fulltextAn experimental approach to evaluate the average energy required by holes for impact ionization in Al<sub>0.4</sub> Ga<sub>0.6</sub>N alloys is presented. A series of back-illuminated separate absorption and multiplication structures with different thickness of multiplication...
Artikel -
4
Experimental validation of cuproptosis-associated molecular signatures and their immunological implications in pulmonary tuberculosis
Publicerad 2025-07-01Hämta fulltextBackgroundThe pathogenic mechanism underlying Mycobacterium tuberculosis (MTB) remains elusive, posing challenges to its diagnosis and treatment. Cuproptosis is a newly identified mechanism of cell death. This study explores the role of cuproptosis-related genes (CRGs) in pulmonary tuberculosis (PTB...
Artikel -
5
Chidamide, a Histone Deacetylase Inhibitor, Combined With R‐GemOx in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma (TRUST): A Multicenter, Single‐Arm, Phase 2 Trial
Publicerad 2025-05-01Hämta fulltextABSTRACT Background Histone deacetylase (HDAC) inhibitors demonstrated a synergistic anti‐tumor effect with rituximab and chemotherapy in preclinical studies on diffuse large B‐cell lymphoma (DLBCL). This phase 2 trial aimed to evaluate the efficacy and safety of chidamide, an orally active HDAC inh...
Artikel